These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

360 related articles for article (PubMed ID: 28659544)

  • 1. Lenvatinib induces early tumor shrinkage in patients with advanced thyroid carcinoma.
    Masaki C; Sugino K; Saito N; Saito Y; Tanaka T; Ogimi Y; Maeda T; Osaku T; Akaishi J; Hames KY; Tomoda C; Suzuki A; Matsuzu K; Uruno T; Ohkuwa K; Kitagawa W; Nagahama M; Takami H; Ito K
    Endocr J; 2017 Aug; 64(8):819-826. PubMed ID: 28659544
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Thyroglobulin fluctuations in patients with iodine-refractory differentiated thyroid carcinoma on lenvatinib treatment - initial experience.
    Werner RA; Lückerath K; Schmid JS; Higuchi T; Kreissl MC; Grelle I; Reiners C; Buck AK; Lapa C
    Sci Rep; 2016 Jun; 6():28081. PubMed ID: 27306607
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Factors involved in early lenvatinib dose reduction: a retrospective analysis.
    Suyama K; Tomiguchi M; Takeshita T; Sueta A; Yamamoto-Ibusuki M; Shimokawa M; Yamamoto Y; Iwase H
    Med Oncol; 2018 Jan; 35(3):19. PubMed ID: 29387983
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [18F]-FDG-PET/CT Correlates With the Response of Radiorefractory Thyroid Cancer to Lenvatinib and Patient Survival.
    Valerio L; Guidoccio F; Giani C; Tardelli E; Puccini G; Puleo L; Minaldi E; Boni G; Elisei R; Volterrani D
    J Clin Endocrinol Metab; 2021 Jul; 106(8):2355-2366. PubMed ID: 33901285
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lesion-Based Evaluation Predicts Treatment Response to Lenvatinib for Radioactive Iodine-Refractory Differentiated Thyroid Cancer: A Korean Multicenter Retrospective Study.
    Lee EK; Kim SM; Kim BH; Kim MJ; Lim DJ; Kim MH; Shin DY; Kang HC; Ahn BC; Kim SW; Ahn HY; Park YJ
    Thyroid; 2019 Dec; 29(12):1811-1819. PubMed ID: 31482759
    [No Abstract]   [Full Text] [Related]  

  • 6. Lenvatinib: Role in thyroid cancer and other solid tumors.
    Cabanillas ME; Habra MA
    Cancer Treat Rev; 2016 Jan; 42():47-55. PubMed ID: 26678514
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tyrosine kinase inhibitors rechallenge in solid tumors: a review of literature and a case description with lenvatinib in thyroid cancer.
    Felicetti F; Nervo A; Piovesan A; Berardelli R; Marchisio F; Gallo M; Arvat E
    Expert Rev Anticancer Ther; 2017 Dec; 17(12):1093-1098. PubMed ID: 28988510
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and Limitations of Lenvatinib Therapy for Radioiodine-Refractory Differentiated Thyroid Cancer: Real-World Experiences.
    Masaki C; Sugino K; Saito N; Akaishi J; Hames KY; Tomoda C; Suzuki A; Matsuzu K; Uruno T; Ohkuwa K; Kitagawa W; Nagahama M; Ito K
    Thyroid; 2020 Feb; 30(2):214-221. PubMed ID: 31854270
    [No Abstract]   [Full Text] [Related]  

  • 9. Drug safety evaluation of lenvatinib for thyroid cancer.
    Krajewska J; Kukulska A; Jarzab B
    Expert Opin Drug Saf; 2015; 14(12):1935-43. PubMed ID: 26484847
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Salvage Lenvatinib Therapy in Metastatic Anaplastic Thyroid Cancer.
    Iñiguez-Ariza NM; Ryder MM; Hilger CR; Bible KC
    Thyroid; 2017 Jul; 27(7):923-927. PubMed ID: 28471306
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tyrosine kinase inhibitors in iodine-refractory differentiated thyroid cancer: experience in clinical practice.
    Molina-Vega M; García-Alemán J; Sebastián-Ochoa A; Mancha-Doblas I; Trigo-Pérez JM; Tinahones-Madueño F
    Endocrine; 2018 Feb; 59(2):395-401. PubMed ID: 29275532
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Phase II Trial of the Multitargeted Tyrosine Kinase Inhibitor Lenvatinib (E7080) in Advanced Medullary Thyroid Cancer.
    Schlumberger M; Jarzab B; Cabanillas ME; Robinson B; Pacini F; Ball DW; McCaffrey J; Newbold K; Allison R; Martins RG; Licitra LF; Shah MH; Bodenner D; Elisei R; Burmeister L; Funahashi Y; Ren M; O'Brien JP; Sherman SI
    Clin Cancer Res; 2016 Jan; 22(1):44-53. PubMed ID: 26311725
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical factors related to the efficacy of tyrosine kinase inhibitor therapy in radioactive iodine refractory recurrent differentiated thyroid cancer patients.
    Sugino K; Nagahama M; Kitagawa W; Ohkuwa K; Uruno T; Matsuzu K; Suzuki A; Masaki C; Akaishi J; Hames KY; Tomoda C; Ogimi Y; Ito K
    Endocr J; 2018 Mar; 65(3):299-306. PubMed ID: 29269689
    [TBL] [Abstract][Full Text] [Related]  

  • 14. OPTIMIZING LENVATINIB THERAPY IN PATIENTS WITH METASTATIC RADIOACTIVE IODINE-RESISTANT DIFFERENTIATED THYROID CANCERS.
    Jasim S; Iniguez-Ariza NM; Hilger CR; Chintakuntlawar AV; Ryder MM; Morris JC; Bible KC
    Endocr Pract; 2017 Oct; 23(10):1254-1261. PubMed ID: 28816536
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lenvatinib in the Therapy of Aggressive Thyroid Cancer: State of the Art and New Perspectives with Patents Recently Applied.
    Ferrari SM; Ruffilli I; Centanni M; Virili C; Materazzi G; Alexopoulou M; Miccoli M; Antonelli A; Fallahi P
    Recent Pat Anticancer Drug Discov; 2018; 13(2):201-208. PubMed ID: 29468981
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lenvatinib: a new option for the treatment of advanced iodine refractory differentiated thyroid cancer?
    Lorusso L; Newbold K
    Future Oncol; 2015; 11(12):1719-27. PubMed ID: 26075440
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Early prediction of lenvatinib treatment efficacy by using
    Takeuchi S; Shiga T; Hirata K; Taguchi J; Magota K; Ariga S; Gouda T; Ohhara Y; Homma R; Shimizu Y; Kinoshita I; Tsuji Y; Homma A; Iijima H; Tamaki N; Dosaka-Akita H
    BMJ Open; 2018 Aug; 8(8):e021001. PubMed ID: 30166292
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combination of Lenvatinib and Pembrolizumab Is an Effective Treatment Option for Anaplastic and Poorly Differentiated Thyroid Carcinoma.
    Dierks C; Seufert J; Aumann K; Ruf J; Klein C; Kiefer S; Rassner M; Boerries M; Zielke A; la Rosee P; Meyer PT; Kroiss M; Weißenberger C; Schumacher T; Metzger P; Weiss H; Smaxwil C; Laubner K; Duyster J; von Bubnoff N; Miething C; Thomusch O
    Thyroid; 2021 Jul; 31(7):1076-1085. PubMed ID: 33509020
    [No Abstract]   [Full Text] [Related]  

  • 19. A Phase II study of the safety and efficacy of lenvatinib in patients with advanced thyroid cancer.
    Takahashi S; Kiyota N; Yamazaki T; Chayahara N; Nakano K; Inagaki L; Toda K; Enokida T; Minami H; Imamura Y; Fukuda N; Sasaki T; Suzuki T; Ikezawa H; Dutcus CE; Tahara M
    Future Oncol; 2019 Mar; 15(7):717-726. PubMed ID: 30638399
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rapid Control of T3 Thyrotoxicosis in Patients with Metastatic Follicular Thyroid Cancer Treated with Lenvatinib.
    Danilovic DL; de Camargo RY; Castro G; Papadia C; Marui S; Hoff AO
    Thyroid; 2015 Nov; 25(11):1262-4. PubMed ID: 26357945
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 18.